4.3 Article

Liver Transplantation for Hilar Cholangiocarcinoma

Related references

Note: Only part of the references are listed.
Review Oncology

Neoadjuvant Therapy Regimens for Hilar Cholangiocarcinoma Before Liver Transplant

Samuel J. Keltner et al.

Summary: The use of neoadjuvant radiation therapy for patients with unresectable hilar cholangiocarcinoma before liver transplantation varies greatly. Different radiation doses and fractionation schemes are utilized, with cumulative doses ranging from 40 to 110 Gy (EQD2). Further studies are needed to evaluate the efficacy and toxicity of these different approaches and provide better guidance for best practices.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2023)

Article Gastroenterology & Hepatology

AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma

Christopher L. Bowlus et al.

HEPATOLOGY (2023)

Article Oncology

Neoadjuvant therapy use and association with postoperative outcomes and overall survival in patients with extrahepatic cholangiocarcinoma

Casey M. Silver et al.

Summary: The study aimed to investigate the trends in neoadjuvant therapy (NAT) for extrahepatic cholangiocarcinoma (eCCA), identify factors associated with the receipt of NAT, and evaluate the associations between NAT and postoperative outcomes. The results showed an increase in the use of NAT over time, with neoadjuvant chemoradiation (CRT) associated with improved postoperative outcomes compared to surgery first.

JOURNAL OF SURGICAL ONCOLOGY (2023)

Article Surgery

Liver Transplantation as a New Standard of Care in Patients With Perihilar Cholangiocarcinoma? Results From an International Benchmark Study

Eva Breuer et al.

Summary: This multicenter benchmark study demonstrates that liver transplantation offers excellent outcomes with superior oncological results in early stage perihilar cholangiocarcinoma patients, even in candidates for surgery. This provocative observation should lead to a change in available therapeutic algorithms for perihilar cholangiocarcinoma.

ANNALS OF SURGERY (2022)

Article Oncology

Feasibility and Efficacy of Adjuvant Chemotherapy With Gemcitabine After Liver Transplantation for Perihilar Cholangiocarcinoma-A Multi-Center, Randomized, Controlled Trial (pro-duct001)

Moritz Schmelzle et al.

Summary: This study aimed to investigate whether adjuvant chemotherapy can be safely administered after liver transplantation (LT) for perihilar cholangiocarcinoma (PHC). However, the study was prematurely terminated due to slow enrollment, and no definite conclusions could be drawn. Nevertheless, long-term survival data are consistent with available retrospective data and confirm the criteria for LT.

FRONTIERS IN ONCOLOGY (2022)

Article Oncology

Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future

Alessandro Rizzo et al.

Summary: Recent years have witnessed breakthroughs in the treatment of advanced biliary tract cancer, including targeted therapies based on molecular understanding and the development of novel treatments. This review provides an overview of systemic treatment for metastatic BTC, summarizing recent clinical data on chemotherapy as well as the main results of targeted therapies and immunotherapy.

CURRENT ONCOLOGY (2022)

Article Oncology

Eligibility for Liver Transplantation in Patients with Perihilar Cholangiocarcinoma

Jaynee J. A. Vugts et al.

Summary: This study aimed to estimate the eligibility for liver transplantation in patients with perihilar cholangiocarcinoma (pCCA) in two tertiary referral centers. Only 5% of all patients with pCCA were potentially eligible for liver transplantation under the Mayo criteria, with a median overall survival of about 1 year in non-transplanted patients.

ANNALS OF SURGICAL ONCOLOGY (2021)

Review Gastroenterology & Hepatology

Epidemiology and risk factors: intrahepatic cholangiocarcinoma

Amar Gupta et al.

HEPATOBILIARY SURGERY AND NUTRITION (2017)

Article Surgery

Is Liver Transplantation Appropriate for Patients with Potentially Resectable De Novo Hilar Cholangiocarcinoma?

Kristopher P. Croome et al.

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2015)

Article Gastroenterology & Hepatology

Hilar Cholangiocarcinoma: expert consensus statement

John C. Mansour et al.

Article Gastroenterology & Hepatology

Hilar cholangiocarcinoma: the Memorial Sloan-Kettering Cancer Center experience

Flavio G. Rocha et al.

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2010)

Article Gastroenterology & Hepatology

High lifetime risk of cancer in primary sclerosing cholangitis

Marian M. H. Claessen et al.

JOURNAL OF HEPATOLOGY (2009)

Review Gastroenterology & Hepatology

Surgery for cholangiocarcinoma: the role of liver transplantation

C. B. Rosen et al.

Article Gastroenterology & Hepatology

Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma

Hendrik T. J. Mantel et al.

LIVER TRANSPLANTATION (2007)

Article Gastroenterology & Hepatology

Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures

Laura E. Moreno Luna et al.

GASTROENTEROLOGY (2006)

Article Surgery

Surgical management of hilar cholangiocarcinoma

AW Hemming et al.

ANNALS OF SURGERY (2005)